Increasing data indicate that inflammation and alterations in glutamate neurotransmission
are two novel pathways to pathophysiology in mood disorders. The primary goal of this …

Depression is a prevalent psychiatric disorder that often leads to poor quality of life and
impaired functioning. Treatment during the acute phase of a major depressive episode aims …

Highlights•Monoamine deficiency hypothesis cannot explain the neurobiology of mood
disorders.•Amino acid neurotransmitters are central to the pathophysiology of mood …

Depression is a chronic, recurring, and serious mood disorder that afflicts up to 20% of the
global population. The monoamine hypothesis has dominated our understanding of the …

Comorbidity exists between metabolic disorders and depressive syndrome with unclear
mechanisms. To characterize the causal relationship, we adopted a 12-week high-fat diet …

Major depressive disorder is one of the most prevalent mental health disorders. Monoamine-
based antidepressants were the first drugs developed to treat major depressive disorder …

Mood disorders such as depression are among the most prevalent psychiatric disorders in
the United States, but they are inadequately treated in a substantial proportion of patients …

Depression is currently recognized as a crucial problem in everyday clinical practice, in light
of ever‐increasing rates of prevalence, as well as disability, morbidity, and mortality related …

Background Many studies have recently been conducted to assess the antidepressant
efficacy of glutamate modification in mood disorders. This is an update of a review first …

Background Major depressive disorder (MDD) exerts a high health and financial burden on
society. The conventional pharmacotherapies for MDD are partially effective and the …